Cargando…

Serologic versus molecular testing for screening for hepatitis C virus infection in patients with hematologic malignancies

Testing for antibody against hepatitis C virus (anti-HCV) is a low-cost diagnostic method worldwide; however, an optimal screening test for HCV in patients with cancer has not been established. We sought to identify an appropriate screening test for HCV infection in patients with hematologic maligna...

Descripción completa

Detalles Bibliográficos
Autores principales:	Torres, Harrys A., Angelidakis, Georgios, Jiang, Ying, Economides, Minas, Mustafayev, Khalis, Yibirin, Marcel, Orlowski, Robert, Champlin, Richard, Verstovsek, Srdan, Raad, Issam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478288/ https://www.ncbi.nlm.nih.gov/pubmed/36123927 http://dx.doi.org/10.1097/MD.0000000000030608

Ejemplares similares

1052. Serologic vs. molecular testing for screening for hepatitis C virus infection in patients with hematologic malignancies with and without prior hematopoietic cell transplant recipients
por: Torres, Harrys A, et al.
Publicado: (2020)

The use of Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients with Hepatocellular Carcinoma
por: Economides, Minas, et al.
Publicado: (2017)

288. Hepatitis B Virus Reactivation in Patients with Hematologic Malignancies after Anticancer Therapy Which Included Ibrutinib
por: Malek, Alexandre, et al.
Publicado: (2019)

919. Rates of False-Positive Hepatitis B Surface Antigen Is Low in Cancer Patients
por: Klingen, Joseph, et al.
Publicado: (2021)

Salvage Therapy in Cancer Patients With Hepatitis C Infection Failing Direct-Acting Antivirals: A Prospective Study
por: Pritchard, Haley, et al.
Publicado: (2017)

Direct-acting Antivirals Induce Lymphoproliferative Disease Response in HCV-infected Patients: A Prospective Case Series
por: Hosry, Jeff, et al.
Publicado: (2017)

Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer
por: Dandachi, Dima, et al.
Publicado: (2018)

Invasive Mold Infections (IMIs) of the Central Nervous System (CNS) in Patients with Hematologic Cancer (HC) (2000–2016): Uncommon but Deadly
por: Economides, Minas Platon, et al.
Publicado: (2017)

2228. Late Viral Relapse After Direct-Acting Antiviral Treatment in Hepatitis C Virus-Infected Cancer Patients
por: Angelidakis, Georgios, et al.
Publicado: (2018)

2227. Short-Duration of Direct-Acting Antivirals in Hepatitis C Virus-Infected Cancer Patients
por: Hosry, Jeff, et al.
Publicado: (2018)

Challenge of hepatitis C in Egypt and hepatitis B in Mauritania
por: Raad, Issam I, et al.
Publicado: (2018)

Salvage therapy in cancer patients with hepatitis C without sustained virologic response after direct‐acting antivirals—A prospective study
por: Pritchard, Haley, et al.
Publicado: (2019)

Treating invasive aspergillosis in patients with hematologic malignancy: diagnostic-driven approach versus empiric therapies
por: Dib, Rita Wilson, et al.
Publicado: (2018)

2197. Hepatitis B Reactivation in Patients with Malignancies Undergoing Treatment for Hepatitis C Infection with Direct-Acting Antivirals
por: Pritchard, Haley, et al.
Publicado: (2018)

Comparing Diagnostic-Driven Approaches to Empiric Therapy in the Treatment of Invasive Aspergillosis in Patients with Hematologic Malignancy
por: Dib, Rita Wilson, et al.
Publicado: (2017)

1257. A phase II Prospective Randomized Study to Assess Ceftolozane-Tazobactam in the Management of Febrile Neutropenia in Patients with Hematological Malignancies
por: Chaftari, Anne-Marie, et al.
Publicado: (2020)

1182. The Real-World Use of Isavuconazole as Primary or salvage Therapy of Invasive Fungal infections in High-Risk Patients with Hematologic Malignancy or Stem Cell Transplant
por: dagher, Hiba, et al.
Publicado: (2020)

Hematologic malignancies and Li–Fraumeni syndrome
por: Swaminathan, Mahesh, et al.
Publicado: (2019)

Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression
por: Verstovsek, Srdan
Publicado: (2013)

How I manage anemia related to myelofibrosis and its treatment regimens
por: Verstovsek, Srdan
Publicado: (2023)

Serological Responses and Predictive Factors of Booster COVID-19 Vaccines in Patients with Hematologic Malignancies
por: Huang, Chien-Tzu, et al.
Publicado: (2023)

272. Invasive Pulmonary Aspergillosis: Comparative Analysis in cancer patients with Underlying Hematologic Malignancy vs. Solid Tumor
por: Wilson Dib, Rita, et al.
Publicado: (2019)

Real-World Use of Isavuconazole as Primary Therapy for Invasive Fungal Infections in High-Risk Patients with Hematologic Malignancy or Stem Cell Transplant
por: Dagher, Hiba, et al.
Publicado: (2022)

Ruxolitinib for essential thrombocythemia?
por: Bose, Prithviraj, et al.
Publicado: (2017)

Updates in the management of polycythemia vera and essential thrombocythemia
por: Bose, Prithviraj, et al.
Publicado: (2019)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
por: Bose, Prithviraj, et al.
Publicado: (2020)

MF management
por: Bose, Prithviraj, et al.
Publicado: (2019)

Clinical development and management of adverse events associated with FGFR inhibitors
por: Subbiah, Vivek, et al.
Publicado: (2023)

Serologic Responses to COVID-19 Vaccines in Hematological Patients Are Predominantly Impaired in Lymphoid but not in Myeloid Malignancies
por: Petzer, Verena, et al.
Publicado: (2022)

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
por: Bryan, Jeffrey C., et al.
Publicado: (2016)

The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes
por: Mascarenhas, John O., et al.
Publicado: (2022)

PB2232: A RANDOMIZED, CONTROLLED CLINICAL TRIAL (PHASE 2B) OF NS-018 VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA
por: Palacio, Melisa, et al.
Publicado: (2023)

A Prospective Randomized Study Comparing Ceftolozane/Tazobactam to Standard of Care in the Management of Neutropenia and Fever in Patients With Hematological Malignancies
por: Chaftari, Anne-Marie, et al.
Publicado: (2022)

Pathophysiology of Coagulopathy in Hematological Malignancies and in COVID-19
por: Levi, Marcel
Publicado: (2021)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
por: Ostojic, Alen, et al.
Publicado: (2012)

Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms
por: Bose, Prithviraj, et al.
Publicado: (2020)

Momelotinib: an emerging treatment for myelofibrosis patients with anemia
por: Chifotides, Helen T., et al.
Publicado: (2022)

Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments
por: Chifotides, Helen T., et al.
Publicado: (2023)

Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies
por: Tavitian, Suzanne, et al.
Publicado: (2015)

2226. Immune Checkpoint Inhibitors in Solid Tumor Patients with Chronic Hepatitis C Virus Infection: A Prospective Case-Series
por: Hosry, Jeff, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rdqgs93lhs5b70dd1uum0i8h5n